Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China

CONCLUSION: With worse liver or renal function, AVA had a similar OR/CR rate but a shorter median time to response and fewer adverse events for patients with relapsed/refractory AA.PMID:37719987 | PMC:PMC10503291 | DOI:10.1177/20406207231191310
Source: Adv Data - Category: Epidemiology Authors: Source Type: research